CR Intrinsic Investors is one of SAC Capital's subsidiaries, and one of its foci is on the biopharmaceutical industry. CR Intrinsic has previously employed Mathew Martoma, a portfolio manager who was charged with insider trading by the SEC earlier this year. CR Intrinsic's $600 million settlement was the largest of its kind on record. The fund has an estimated $2 billion to $3 billion in assets under management.
| Fund Name: | CR Intrinsic Investors |
| Manager | Sac Subsidiary |
| Portfolio Value | $0 |
| Change This QTR | 0.00% |
We use tracking technologies to enhance your user experience and to provide you service. By using Insider Monkey, you are giving us consent. Learn More
